|
Gene: GALT |
Gene summary for GALT |
Gene summary. |
Gene information | Species | Human | Gene symbol | GALT | Gene ID | 2592 |
Gene name | galactose-1-phosphate uridylyltransferase | |
Gene Alias | GALT | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | A0A0S2Z3Y7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2592 | GALT | LZE4T | Human | Esophagus | ESCC | 7.97e-06 | 2.81e-01 | 0.0811 |
2592 | GALT | LZE24T | Human | Esophagus | ESCC | 4.81e-06 | 1.73e-01 | 0.0596 |
2592 | GALT | LZE21T | Human | Esophagus | ESCC | 8.53e-04 | 1.81e-01 | 0.0655 |
2592 | GALT | P2T-E | Human | Esophagus | ESCC | 3.02e-33 | 6.77e-01 | 0.1177 |
2592 | GALT | P4T-E | Human | Esophagus | ESCC | 2.83e-07 | 1.24e-01 | 0.1323 |
2592 | GALT | P5T-E | Human | Esophagus | ESCC | 5.98e-12 | 1.18e-01 | 0.1327 |
2592 | GALT | P8T-E | Human | Esophagus | ESCC | 1.07e-08 | 1.11e-01 | 0.0889 |
2592 | GALT | P9T-E | Human | Esophagus | ESCC | 1.63e-07 | 1.68e-01 | 0.1131 |
2592 | GALT | P10T-E | Human | Esophagus | ESCC | 7.34e-15 | 1.24e-01 | 0.116 |
2592 | GALT | P11T-E | Human | Esophagus | ESCC | 2.44e-09 | 2.49e-01 | 0.1426 |
2592 | GALT | P12T-E | Human | Esophagus | ESCC | 5.82e-15 | 3.15e-01 | 0.1122 |
2592 | GALT | P15T-E | Human | Esophagus | ESCC | 3.94e-04 | 9.08e-02 | 0.1149 |
2592 | GALT | P16T-E | Human | Esophagus | ESCC | 3.62e-17 | 2.07e-01 | 0.1153 |
2592 | GALT | P17T-E | Human | Esophagus | ESCC | 7.72e-08 | 1.96e-01 | 0.1278 |
2592 | GALT | P20T-E | Human | Esophagus | ESCC | 6.95e-04 | 1.30e-01 | 0.1124 |
2592 | GALT | P21T-E | Human | Esophagus | ESCC | 1.04e-19 | 2.55e-01 | 0.1617 |
2592 | GALT | P22T-E | Human | Esophagus | ESCC | 2.72e-23 | 2.85e-01 | 0.1236 |
2592 | GALT | P23T-E | Human | Esophagus | ESCC | 5.09e-15 | 1.48e-01 | 0.108 |
2592 | GALT | P24T-E | Human | Esophagus | ESCC | 5.85e-09 | 7.34e-02 | 0.1287 |
2592 | GALT | P26T-E | Human | Esophagus | ESCC | 1.33e-18 | 1.76e-01 | 0.1276 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206028 | Skin | AK | wound healing | 91/1910 | 422/18723 | 2.93e-12 | 6.67e-10 | 91 |
GO:005067319 | Skin | AK | epithelial cell proliferation | 86/1910 | 437/18723 | 1.52e-09 | 1.43e-07 | 86 |
GO:000206425 | Skin | AK | epithelial cell development | 51/1910 | 220/18723 | 1.50e-08 | 9.13e-07 | 51 |
GO:005067818 | Skin | AK | regulation of epithelial cell proliferation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
GO:005090015 | Skin | AK | leukocyte migration | 63/1910 | 369/18723 | 3.00e-05 | 5.15e-04 | 63 |
GO:00506797 | Skin | AK | positive regulation of epithelial cell proliferation | 39/1910 | 207/18723 | 1.18e-04 | 1.49e-03 | 39 |
GO:00447068 | Skin | AK | multi-multicellular organism process | 36/1910 | 220/18723 | 2.97e-03 | 1.87e-02 | 36 |
GO:0034655111 | Skin | cSCC | nucleobase-containing compound catabolic process | 172/4864 | 407/18723 | 4.11e-13 | 2.43e-11 | 172 |
GO:0046700110 | Skin | cSCC | heterocycle catabolic process | 178/4864 | 445/18723 | 4.45e-11 | 2.13e-09 | 178 |
GO:0044270110 | Skin | cSCC | cellular nitrogen compound catabolic process | 179/4864 | 451/18723 | 8.34e-11 | 3.79e-09 | 179 |
GO:0019439110 | Skin | cSCC | aromatic compound catabolic process | 183/4864 | 467/18723 | 1.76e-10 | 7.68e-09 | 183 |
GO:1901361110 | Skin | cSCC | organic cyclic compound catabolic process | 188/4864 | 495/18723 | 1.92e-09 | 7.01e-08 | 188 |
GO:190290329 | Skin | cSCC | regulation of supramolecular fiber organization | 145/4864 | 383/18723 | 1.67e-07 | 3.71e-06 | 145 |
GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
GO:1902905112 | Skin | cSCC | positive regulation of supramolecular fiber organization | 83/4864 | 209/18723 | 8.87e-06 | 1.17e-04 | 83 |
GO:00064877 | Skin | cSCC | protein N-linked glycosylation | 33/4864 | 65/18723 | 1.63e-05 | 1.99e-04 | 33 |
GO:000206426 | Skin | cSCC | epithelial cell development | 84/4864 | 220/18723 | 4.33e-05 | 4.56e-04 | 84 |
GO:005067324 | Skin | cSCC | epithelial cell proliferation | 144/4864 | 437/18723 | 6.07e-04 | 4.38e-03 | 144 |
GO:000941621 | Skin | cSCC | response to light stimulus | 107/4864 | 320/18723 | 1.66e-03 | 1.02e-02 | 107 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012505 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa0125012 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa012504 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa0125011 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALT | insertion | Frame_Shift_Ins | novel | c.550_551insCTTTTCCAAGCAAAGTCTGCTCGAGGAGTCTGGT | p.His184ProfsTer30 | p.H184Pfs*30 | P07902 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
GALT | SNV | Missense_Mutation | novel | c.268N>A | p.Asp90Asn | p.D90N | P07902 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GALT | SNV | Missense_Mutation | novel | c.46G>C | p.Glu16Gln | p.E16Q | P07902 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.703) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GALT | SNV | Missense_Mutation | novel | c.877T>G | p.Ser293Ala | p.S293A | P07902 | protein_coding | deleterious(0.04) | probably_damaging(0.945) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GALT | SNV | Missense_Mutation | c.1078G>A | p.Ala360Thr | p.A360T | P07902 | protein_coding | tolerated(0.43) | benign(0.02) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GALT | SNV | Missense_Mutation | c.566N>C | p.Val189Ala | p.V189A | P07902 | protein_coding | deleterious(0) | benign(0.088) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALT | SNV | Missense_Mutation | c.507N>T | p.Gln169His | p.Q169H | P07902 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALT | SNV | Missense_Mutation | rs111033686 | c.413N>T | p.Thr138Met | p.T138M | P07902 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-DC-6154-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2592 | GALT | ENZYME | HyperAcute vaccine | |||
2592 | GALT | ENZYME | Algenpantucel-L | ALGENPANTUCEL-L | 24343588 |
Page: 1 |